ACCEPT DECLINE
Change Visitor Type

Portfolio

Scancell

Scancell floated on the PLUS stock exchange in September 2008, raising £1.6m, and moved to AIM in July 2010. Oxford Capital sold the majority of its position during 2012.

Scancell was spin-out from Nottingham University which developed and patented a revolutionary therapeutic vaccine technology – the ImmunoBody platform – that overcomes the limitations of many existing therapeutic vaccines. Scancell’s first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. The initial results have been highly encouraging and suggest that SCIB1 could have an important future role as first line treatment for patients with resected Stage II or III disease, a key area of unmet medical need for which there are no effective and safe treatment options available.

3
  • Push Dr primed to assist GPs to switch to digital consultations to combat Covid-19


    Read more
  • Curve Review – Is it the best way to combine all your cards?


    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more
  • Wrisk has been announced as a finalist in the Insurtech category at the UK Fintech Awards 2020


    Read more
  • Read an interview with Rahul Powar at RedSift on Democratizing Data & Harnessing it for Email Security


    Read more
  • Waymo acquires Latent Logic to accelerate progress towards safe, driveless vehicles


    Read more
  • 2 of Oxford Capital’s portfolio highlighted in Britain’s Top 100 fastest growing businesses


    Read more